MedTrace Logo

An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS

NCT00754273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1250

Last updated 2011-03-23

No results posted yet for this study

Summary

To determine the prevalence of MRSA isolates with marginal susceptibility to vancomycin or heteroresistance.

Conditions

  • Methicillin-resistant Staphylococcal Aureus Pneumonia

Interventions

OTHER

etest susceptability testing

E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Kentucky

    lead OTHER

Principal Investigators

  • Andrew C. Bernard, M.D. · University of Kentucky

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754273 on ClinicalTrials.gov